MedWatch

Analyst on Coloplast: Very good financial report was helped by favorable currency rates

Medtech company Coloplast lifted its organic growth over the market’s estimates in Q1, and the company could also add a little to the top line due to positive currency fluctuations. All in all, Coloplast’s report is very good, says Analyst Søren Løntoft Hansen.

Photo: Sydbank/PR

Positive currency fluctuations – driven by a strong American dollar – have helped lift the medtech company’s top line in the first quarter of financial 2021/2022, where the company’s revenue beat expectations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs